Aclaris Therapeutics is a diagnostics & research business based in the US. Aclaris Therapeutics shares (ACRS) are listed on the NASDAQ and all prices are listed in US Dollars. Aclaris Therapeutics employs 72 staff and has a trailing 12-month revenue of around $23.5 million.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $16.82 |
|---|---|
| 52-week range | $9.84 - $18.96 |
| 50-day moving average | $16.36 |
| 200-day moving average | $15.36 |
| Wall St. target price | $32.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.36 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $16.82 from 2023-01-26
| 1 week (2023-01-20) | 1.02% |
|---|---|
| 1 month (2022-12-27) | 11.91% |
| 3 months (2022-10-27) | 17.38% |
| 6 months (2022-07-27) | 5.92% |
| 1 year (2022-01-27) | 66.53% |
|---|---|
| 2 years (2021-01-27) | -8.79% |
| 3 years (2020-01-27) | 1,044.22% |
| 5 years (2018-01-26) | 24.53 |
| Revenue TTM | $23.5 million |
|---|---|
| Gross profit TTM | $-41,765,000 |
| Return on assets TTM | -19.74% |
| Return on equity TTM | -37.61% |
| Profit margin | 0% |
| Book value | $3.30 |
| Market capitalisation | $1.1 billion |
TTM: trailing 12 months
We're not expecting Aclaris Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Aclaris Therapeutics's shares have ranged in value from as little as $9.84 up to $18.958. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aclaris Therapeutics's is 0.5849. This would suggest that Aclaris Therapeutics's shares are less volatile than average (for this exchange).
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
